Ponatinib reduces viability, migration, and functionality of human endothelial cells.
about
Second line small molecule therapy options for treating chronic myeloid leukemia.The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.Ponatinib Activates an Inflammatory Response in Endothelial Cells via ERK5 SUMOylation
P2860
Ponatinib reduces viability, migration, and functionality of human endothelial cells.
description
2016 nî lūn-bûn
@nan
2016 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Ponatinib reduces viability, migration, and functionality of human endothelial cells.
@ast
Ponatinib reduces viability, migration, and functionality of human endothelial cells.
@en
type
label
Ponatinib reduces viability, migration, and functionality of human endothelial cells.
@ast
Ponatinib reduces viability, migration, and functionality of human endothelial cells.
@en
prefLabel
Ponatinib reduces viability, migration, and functionality of human endothelial cells.
@ast
Ponatinib reduces viability, migration, and functionality of human endothelial cells.
@en
P2093
P2860
P1433
P1476
Ponatinib reduces viability, migration, and functionality of human endothelial cells.
@en
P2093
Aida Inbal
Arnon Nagler
Avi Leader
Ayala Gover-Proaktor
Dorit L Lev
Galit Granot
Oren Pasvolsky
Oshrat Raz
Pia Raanani
P2860
P304
P356
10.1080/10428194.2016.1239258
P577
2016-10-12T00:00:00Z